var data={"title":"Diltiazem: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Diltiazem: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6038?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=diltiazem-patient-drug-information\" class=\"drug drug_patient\">see &quot;Diltiazem: Patient drug information&quot;</a> and <a href=\"topic.htm?path=diltiazem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diltiazem: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160657\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cardizem;</li>\n      <li>Cardizem CD;</li>\n      <li>Cardizem LA;</li>\n      <li>Cartia XT;</li>\n      <li>Dilacor XR [DSC];</li>\n      <li>Dilt-XR;</li>\n      <li>DilTIAZem CD;</li>\n      <li>Matzim LA;</li>\n      <li>Taztia XT;</li>\n      <li>Tiazac</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160658\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Diltiazem CD;</li>\n      <li>ACT Diltiazem T;</li>\n      <li>Apo-Diltiaz;</li>\n      <li>Apo-Diltiaz CD;</li>\n      <li>Apo-Diltiaz SR;</li>\n      <li>Apo-Diltiaz TZ;</li>\n      <li>Cardizem CD;</li>\n      <li>Diltiazem Hydrochloride Injection;</li>\n      <li>Diltiazem TZ;</li>\n      <li>Diltiazem-CD;</li>\n      <li>PMS-Diltiazem CD;</li>\n      <li>Sandoz-Diltiazem CD;</li>\n      <li>Sandoz-Diltiazem T;</li>\n      <li>Teva-Diltiazem;</li>\n      <li>Teva-Diltiazem CD;</li>\n      <li>Teva-Diltiazem HCL ER Capsules;</li>\n      <li>Tiazac;</li>\n      <li>Tiazac XC</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160711\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antianginal Agent;</li>\n      <li>\n        Antiarrhythmic Agent, Class IV;</li>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Calcium Channel Blocker;</li>\n      <li>\n        Calcium Channel Blocker, Nondihydropyridine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160662\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angina:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Capsule, extended release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dilacor XR, Dilt-XR: Initial: 120 mg once daily; titrate over 7 to 14 days; usual dose range (ACC/AHA [Gibbons 2003]): 120 to 320 mg daily: maximum: 480 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardizem CD, Cartia XT: Initial: 120 to 180 mg once daily; titrate over 7 to 14 days; usual dose range (ACC/AHA [Gibbons 2003]): 120 to 320 mg daily; maximum: 480 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tiazac, Taztia XT: Initial: 120 to 180 mg once daily; titrate over 7 to 14 days; usual dose range (ACC/AHA [Gibbons 2003]): 120 to 320 mg daily; maximum: 540 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablet, extended release</i> (Cardizem LA, Matzim LA, Tiazac XC [Canadian product]): Initial: 180 mg once daily; may increase at 7- to 14-day intervals; usual dose range (ACC/AHA [Gibbons 2003]): 120 to 320 mg/day; maximum: 360 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablet, immediate release </i>(Cardizem): Initial: 30 mg 4 times daily; titrate dose gradually at 1- to 2-day intervals; usual dose range (ACC/AHA [Gibbons 2003]): 120 to 320 mg daily in 4 divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Capsule, extended release (once-daily dosing):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cardizem CD, Cartia XT: Initial: 180 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range (ASH/ISH [Weber 2014]): 240 to 360 mg daily; maximum: 480 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dilacor XR, Dilt-XR: Initial: 180 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range (ASH/ISH [Weber 2014]): 240 to 360 mg daily; maximum: 540 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tiazac, Taztia XT: Initial: 120 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range (ASH/ISH [Weber 2014]): 240 to 360 mg daily; maximum: 540 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Capsule, extended release (twice-daily dosing):</i> Initial: 60 to 120 mg twice daily; dose adjustment may be made after 14 days; usual range: 240 to 360 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Diltiazem is available as a generic intended for either once- or twice-daily dosing, depending on the formulation; verify appropriate extended release capsule formulation is administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablet, extended release</i> (Cardizem LA, Matzim LA, Tiazac XC [Canadian product]): Initial: 180 to 240 mg once daily; dose adjustment may be made after 14 days; usual dose range (ASH/ISH [Weber 2014]): 240 to 360 mg daily; maximum: 540 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation, atrial flutter, PSVT (acute treatment):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Control of rapid ventricular rate in atrial fibrillation or atrial flutter or conversion of PSVT: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Initial bolus dose:</i> 0.25 mg/kg actual body weight over 2 minutes (average adult dose: 20 mg); ACLS guideline recommends 15 to 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Repeat bolus dose (may be administered after 15 minutes if the response is inadequate):</i> 0.35 mg/kg actual body weight over 2 minutes (average adult dose: 25 mg); ACLS guideline recommends 20 to 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Continuous infusion (infusions &gt;24 hours or infusion rates &gt;15 mg/hour are not recommended):</i> Initial infusion rate of 10 mg/hour; rate may be increased in 5 mg/hour increments up to 15 mg/hour as needed; some patients may respond to an initial rate of 5 mg/hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If diltiazem injection is administered by continuous infusion for &gt;24 hours, the possibility of decreased diltiazem clearance, prolonged elimination half-life, and increased diltiazem and/or diltiazem metabolite plasma concentrations should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (rate control) (off-label use):</b> Oral: Extended release (capsule or tablet): Usual maintenance dose: 120 to 360 mg once daily (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Supraventricular tachycardia (ongoing management)</b> <b>(off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release (capsule or tablet):</i> Initial: 120 mg daily in divided doses or once daily; usual maintenance dose: 360 mg daily in divided doses or once daily (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial: 120 mg daily in divided doses; usual maintenance dose: 360 mg daily in divided doses (ACC/AHA/HRS [Page 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion from IV diltiazem to oral diltiazem:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral dose (mg daily) is approximately equal to [rate (mg/hour) x 3 + 3] x 10</i>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 mg/hour = 120 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 mg/hour = 180 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">7 mg/hour = 240 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">11 mg/hour = 360 mg daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160686\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=diltiazem-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Diltiazem: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension (off-label use):</b> Children and Adolescents: Minimal information available: Oral: Initial: 1.5 to 2 mg/kg/day in 3 to 4 divided doses (extended release formulations may be dosed once or twice daily); maximum dose: 3.5 mg/kg/day; some centers use a maximum dose of 6 mg/kg/day up to 360 mg/day (Flynn 2000).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160663\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 120 mg once daily using extended release capsule) and titrate to response (Aronow 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160664\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160665\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustment provided in the manufacturer&rsquo;s labeling; use with caution; extensively metabolized by the liver; half-life is increased in patients with cirrhosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160628\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 12 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 60 mg, 90 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem CD: 120 mg, 180 mg, 240 mg, 300 mg [DSC], 360 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cartia XT: 120 mg, 180 mg, 240 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cartia XT: 300 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilacor XR: 240 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilt-XR: 120 mg, 180 mg, 240 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DilTIAZem CD: 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DilTIAZem CD: 180 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DilTIAZem CD: 240 mg, 300 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taztia XT: 120 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taztia XT: 180 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taztia XT: 240 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taztia XT: 300 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Taztia XT: 360 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tiazac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL); 125 mg/25 mL (25 mL); 100 mg/100 mL in Dextrose 5% (100 mL); 100 mg/100 mL in NaCl 0.9% (100 mL); 125 mg/125 mL (125 mL); 125 mg/125 mL in NaCl 0.9% (125 mL); 250 mg/250 mL in Dextrose 5% (250 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/10 mL (10 mL [DSC]); 125 mg/25 mL (25 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem: 30 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem: 30 mg [contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem: 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem: 60 mg [scored; contains fd&amp;c blue #1 aluminum lake, fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem: 120 mg [scored; contains fd&amp;c yellow #10 aluminum lake, fd&amp;c yellow #6 aluminum lake, methylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 30 mg, 60 mg, 90 mg, 120 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem LA: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Matzim LA: 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160613\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6047983\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Extended Release, Oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tiazac XC: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160632\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate release tablet (eg, Cardizem): Administer before meals and at bedtime. The manufacturers of the film-coated tablets recommend to swallow the tablet whole; do not split, crush, or chew. According to these manufacturers, crushing immediate release tablets may alter pharmacokinetics. However, crushing tablets that are prepared using a direct compression technique is acceptable. An oral suspension has been made using the immediate release tablets manufactured using a direct compression technique (Allen 1996). Brand name Cardizem tablets are prepared using a direct compression technique and may be crushed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Long acting dosage forms: Do not open, chew, or crush; swallow whole. Administer at same time of day either morning or evening.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Cardizem CD, Cardizem LA, Cartia XT, Matzim LA: Administer without regard to meals. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dilacor XR: Administer on an empty stomach.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dilt XR: Administer on an empty stomach in the morning.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Taztia XT, Tiazac: Capsules may be opened and sprinkled on a spoonful of applesauce. Applesauce should not be hot and should be swallowed without chewing, followed by drinking a glass of water.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Tiazac XC [Canadian product]: Administer at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Bolus doses given over 2 minutes with continuous ECG and blood pressure monitoring. Continuous infusion should be via infusion pump. May increase infusion rate in 5 mg/hour increments as needed (maximum: 15 mg/hour). Response to bolus may require several minutes to reach maximum. Response may persist for several hours after infusion is discontinued.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14471309\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 125 mg in 125 mL (total volume) (concentration: 1 mg/mL) of D<sub>5</sub>W or  NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160631\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Management of hypertension (monotherapy or in combination with other antihypertensives); management of chronic stable angina or angina from coronary artery spasm.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Guideline recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypertension: The 2014 guideline for the management of high blood pressure in adults (JNC 8) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC8 [James 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull;  Patients &ge;60 years of age, with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg. Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull;  Patients &lt;60 years of age, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Patients &ge;18 years of age with diabetes, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&bull;  Patients &ge;18 years of age with chronic kidney disease (CKD), with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Chronic kidney disease (CKD) and hypertension: Regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general nonblack population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker <b>instead of</b> an ACEI or ARB.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coronary artery disease (CAD) and hypertension: The American Heart Association, American College of Cardiology and American Society of Hypertension (AHA/ACC/ASH) 2015 scientific statement for the treatment of hypertension in patients with coronary artery disease (CAD) recommends that a non-dihydropyridine CCB (verapamil, diltiazem) may be used as a substitute for a beta blocker in patients who have an intolerance or contraindication to beta blockers with ongoing ischemia, hypertension and chronic stable angina, or if angina or hypertension continues to be uncontrolled while receiving standard therapies (eg, beta blocker).  However, a non-dihydropyridine CCB (eg, verapamil, diltiazem) should be avoided in patients with LV dysfunction or heart failure (with reduced ejection fraction). A BP target of &lt;140/90 mm Hg is reasonable for the secondary prevention of cardiovascular events. A lower target BP (&lt;130/80 mm Hg) may be appropriate in some individuals with CAD, previous MI, stroke or transient ischemic attack, or CAD risk equivalents (AHA/ACC/ASH [Rosendorff 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Injection: Control of rapid ventricular rate in patients with atrial fibrillation or atrial flutter; conversion of paroxysmal supraventricular tachycardia (PSVT)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Guideline recommendations: </i>ACC/AHA/HRS supraventricular tachycardia (SVT) guidelines recommends IV diltiazem as a therapeutic option for the acute treatment (ie, conversion) of a variety of SVTs (AVNRT, AVRT, and focal AT) in hemodynamically stable patients. Diltiazem is not appropriate for patients with suspected systolic heart failure or pre-excitation on ECG (ACC/AHA/HRS [Page 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475027\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anal fissures (topical); Atrial fibrillation (rate control) (oral); Hypertrophic cardiomyopathy; Non-ST-elevation acute coronary syndrome; Raynaud phenomenon; Stable narrow-complex tachycardia uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent (injection); Supraventricular tachycardia (AV nodal reentrant tachycardia [AVNRT], AV reentrant tachycardia [AVRT], focal atrial tachycardia [AT], multifocal atrial tachycardia [MAT]) (ongoing management) (oral); Hypertension (Children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160720\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem may be confused with Cardene, Cardene SR, Cardizem CD, Cardizem SR, cortisone </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cartia XT may be confused with Procardia XL</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DilTIAZem may be confused with Calan, diazePAM, Dilantin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tiazac may be confused with Tigan, Tiazac XC [CAN], Ziac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardizem [US, Canada, and multiple international markets] may be confused with Cardem brand name for celiprolol [Spain]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cartia XT [US] may be confused with Cartia brand name for aspirin [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dilacor XR [U.S.]  may be confused with Dilacor brand name for verapamil [Brazil] </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dipen [Greece] may be confused with Depen brand name for penicillamine [US]; Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tiazac: Brand name for dilTIAZem [US, Canada], but also the brand name for pioglitazone [Chile]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160620\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequencies represent ranges for various dosage forms. Patients with impaired ventricular function and/or conduction abnormalities may have higher incidence of adverse reactions. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (2% to 15%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (5% to 12%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">2% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Atrioventricular block (2% to 8%; first degree), edema (2% to 8%; lower limb), bradycardia (2% to 6%), hypotension (&lt;2% to 4%), vasodilatation (2% to 3%), extrasystoles (2%), flushing (1% to 2%), palpitations (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (3% to 10%), pain (6%), nervousness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (1% to 4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gout (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (1% to 6%), constipation (&lt;2% to 4%), vomiting (2%), diarrhea (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Injection site reaction (4%; itching, burning) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (1% to 4%), myalgia (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinitis (&lt;2% to 10%), pharyngitis (2% to 6%), dyspnea (1% to 6%), bronchitis (1% to 4%), cough (&le;3), sinus congestion (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;2%, postmarketing, and/or case reports: Abnormal dreams, abnormal gait, albuminuria, alopecia, amblyopia, amnesia, angina pectoris, angioedema, anorexia, asystole, atrioventricular block (second or third degree), bruise, bundle branch block, cardiac arrhythmia, cardiac failure, crystalluria, depression, drowsiness, dysgeusia, ECG abnormality, epistaxis, erythema multiforme, exfoliative dermatitis, extrapyramidal reaction, gingival hyperplasia, gynecomastia, hallucination, hemolytic anemia, hyperglycemia, hypersensitivity angiitis, hypersensitivity reaction, hyperuricemia, impotence, increased creatine phosphokinase, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum bilirubin, increased thirst, insomnia, leukopenia, muscle cramps, myopathy, nausea, neck stiffness, nocturia, pain, paresthesia, personality changes, petechia, polyuria, prolonged bleeding time, pruritus, purpura, retinopathy, skin photosensitivity, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tinnitus, toxic epidermal necrolysis, tremor, urticaria, ventricular premature contractions, weight gain, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160636\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); hypotension (systolic &lt;90 mm Hg); acute MI and pulmonary congestion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravenous (IV): Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); severe hypotension; cardiogenic shock; administration concomitantly or within a few hours of the administration of IV beta-blockers; atrial fibrillation or flutter associated with accessory bypass tract (eg, Wolff-Parkinson-White syndrome, short PR syndrome); ventricular tachycardia (with wide-complex tachycardia [QRS &ge;0.12 seconds], must determine whether origin is supraventricular or ventricular)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; use in women of childbearing potential; concurrent use with intravenous dantrolene; concurrent use with ivabradine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160617\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction abnormalities: May cause first-, second-, and third-degree AV block or sinus bradycardia; risk increases with agents known to slow cardiac conduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Transient dermatologic reactions have been observed with use; if reaction persists, discontinue. Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, and/or exfoliative dermatitis have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic effects: Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed and frequently resolve spontaneously. Significant elevations in hepatic transaminases (eg, alkaline phosphatase, LDH, AST,  ALT) and signs of acute hepatic injury have also been observed 1 to 8 weeks after therapy initiation and have been reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertrophic obstructive cardiomyopathy (HOCM): Use with caution in patients with HOCM; routine use is currently not recommended due to insufficient evidence (Maron 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Left ventricular dysfunction: Use with caution in left ventricular dysfunction; due to negative inotropic effects, may exacerbate condition. The ACCF/AHA heart failure guidelines recommend to avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: IV: Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of IV diltiazem. Use with caution in patients hemodynamically compromised; continuously monitor ECG and blood pressure during administration (especially during continuous IV infusion). Initial use should be, if possible, in a setting where monitoring and resuscitation equipment, including DC cardioversion/defibrillation, are present.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160705\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160622\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9365&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: DilTIAZem may increase the serum concentration of Alfentanil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Fluconazole and isavuconazonium likely exert weaker effects than other azoles and are addressed in separate monographs. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.<b> Exceptions: </b>Fluconazole; Isavuconazonium Sulfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Calcium Channel Blockers (Nondihydropyridine) may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May increase the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of AtorvaSTATin. Management: Consider using lower atorvastatin doses when used together with diltiazem.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Calcium Channel Blockers (Nondihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended. See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor.  The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical).  Management: Per US prescribing information, avoid this combination. Canadian product labeling does not recommend strict avoidance. If combined, monitor for excessive glucocorticoid effects as budesonide exposure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for increased toxic effects of carbamazepine and reduced therapeutic effects of the calcium channel blocker.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in adult patients who are also receiving moderate inhibitors of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloNIDine: May enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid the concomitant use of cobimetinib and moderate CYP3A4 inhibitors. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose to 20 mg daily.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colestipol: May decrease the absorption of DilTIAZem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: DilTIAZem may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): DilTIAZem may increase the serum concentration of Corticosteroids (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inhibitors): CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors). <b> Exceptions: </b>Alitretinoin (Systemic); Praziquantel; Trabectedin; Vinorelbine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine). Management: This interaction has only been described with intravenous dantrolene administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to moderate CYP3A4 inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Use lower starting doses of the nondihydropyridine calcium channel blockers (i.e., verapamil, diltiazem), and only consider increasing calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of DilTIAZem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan.  Management: The use of eletriptan within 72 hours of a moderate CYP3A4 inhibitor should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Use should be avoided under some circumstances.  See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations vary by indication and international labeling. See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esmolol: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Esmolol.  Management: Administration of IV verapamil or diltiazem together with esmolol is contraindicated if one agent is given while the effects of the other are still present. Canadian esmolol labeling specifies that use within 24 hours is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients closely for several days following initiation of this combination, and adjust fentanyl dose as necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: DilTIAZem may enhance the bradycardic effect of Fingolimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of DilTIAZem. The active metabolite aprepitant is likely responsible for this effect. DilTIAZem may increase the serum concentration of Fosaprepitant. Specifically, diltiazem may increase the concentration of the active metabolite aprepitant.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of DilTIAZem.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when initiating this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.  Management: Extreme caution, with possibly increased monitoring of cardiac status (eg, ECG), should be used with concurrent use of halofantrine with any moderate CYP3A4 inhibitor(s).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HydrOXYzine.  Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: DilTIAZem may increase the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Ivabradine. Ivabradine may enhance the QTc-prolonging effect of Calcium Channel Blockers (Nondihydropyridine). Specifically, the QTc prolonging effects of bepridil may be enhanced. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ivabradine. Specifically, verapamil or diltiazem may increase serum ivabradine concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions are required; consult full monograph content for specific age- and weight-based recommendations.  No dose adjustment is needed when using ivacaftor/lumacaftor with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: May increase the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of Lovastatin. Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving diltiazem. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: Lurasidone US labeling recommends reducing lurasidone dose by half with a moderate CYP3A4 inhibitor. Some non-US labeling recommends initiating lurasidone at 20 mg/day and limiting dose to 40 mg/day; avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide.  Felodipine Canadian labeling specifically recommends avoiding its use in combination with clarithromycin.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: DilTIAZem may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and diltiazem if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors in patients being treated with olaparib, if possible.  If such concurrent use cannot be avoided, the dose of olaparib should be reduced to 150 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Opioids (Anilidopiperidine) may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CYP3A4 Inhibitors (Moderate) may enhance the adverse/toxic effect of OxyCODONE. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Calcium Channel Blockers.  Management: Avoid use of nimodipine or nifedipine with phenytoin. Monitor for phenytoin toxicity and/or decreased calcium channel blocker effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade. Management: Avoid concurrent use when possible. If used, monitor for CCB toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir, tipranavir, and darunavir/cobicistat use with bepridil is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: DilTIAZem may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ranolazine.  Management: Limit ranolazine dose to a maximum of 500 mg twice daily when used with diltiazem or verapamil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of DilTIAZem.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: May increase the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of Simvastatin. Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult doses to simvastatin 10 mg/day and diltiazem 240 mg/day; avoid Simcor (simvastatin/niacin) because fixed simvastatin doses exceed the maximum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: DilTIAZem may increase the serum concentration of Sirolimus. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tezacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor.  Management: When combined with moderate CYP3A4 inhibitors, tezacaftor/ivacaftor (100 mg/150 mg) should be given in the morning, every other day. Ivacaftor (150 mg) alone should be given in the evening, every other day, on alternate days from tezacaftor/ivacaftor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal.  Management: This is specific for when ulipristal is being used for signs/symptoms of uterine fibroids (Canadian indication). When ulipristal is used as an emergency contraceptive, patients receiving this combination should be monitored for ulipristal toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone.  Management: The starting adult dose of zopiclone should not exceed 3.75 mg if combined with a moderate CYP3A4 inhibitor. Monitor patients for signs and symptoms of zopiclone toxicity if these agents are combined.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160653\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase the serum concentration of diltiazem. Management: Monitor response to diltiazem with concurrent use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160624\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160639\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Untreated chronic maternal hypertension is associated with adverse events in the fetus, infant, and mother. If treatment for hypertension during pregnancy is needed, other agents are preferred (ACOG 2013). Women with hypertrophic cardiomyopathy who are controlled with diltiazem prior to pregnancy may continue therapy, but increased fetal monitoring is recommended (Gersh 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160640\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Diltiazem is excreted in breast milk in concentrations similar to those in the maternal plasma (Okada 1985). Breast-feeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160626\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Liver function tests, kidney function, blood pressure, ECG, heart rate; consult individual institutional policies and procedures.  Ventricular rate control in patients with atrial fibrillation or flutter: Patients who respond, usually have at least a 20% decrease in ventricular response rate or a rate &lt;100 beats/minute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160616\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces  relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160635\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: Immediate release tablet: 30 to 60 minutes; IV: Bolus: 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IV: Bolus: 1 to 3 hours; Continuous infusion (after discontinuation): 0.5 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Immediate release tablet: ~98%; Extended release capsule: ~93% to &gt;95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 3 to 13 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 70% to 80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (extensive first-pass effect) via CYP-450 and conjugation; forms metabolites N-monodesmethyldiltiazem, desacetyldiltiazem, desacetyl-Nmonodesmethyldiltiazem, desacetyl-O-desmethyldiltiazem, and desacetyl-N, O-desmethyldiltiazem; following single IV injection, plasma concentrations of N-monodesmethyldiltiazem and desacetyldiltiazem are typically undetectable; however, these metabolites accumulate to detectable concentrations following 24-hour constant rate infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: ~40% (undergoes extensive first-pass metabolism)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Immediate release tablet: 3 to 4.5 hours; Extended release tablet: 6 to 9 hours; Extended release capsules: 4 to 9.5 hours; IV: single dose: ~3.4 hours; continuous infusion: 4 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Immediate release tablet: 2 to 4 hours; Extended release tablet: 11 to 18 hours; Extended release capsule: 10 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (2% to 4% as unchanged drug); feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160638\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Cardizem CD Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $895.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $1,129.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (30): $1,531.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (90): $8,780.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Cartia XT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (90): $107.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (90): $130.12</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (90): $184.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (90): $239.24</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (DilTIAZem HCl ER Beads Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (90): $93.31</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (90): $112.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (90): $159.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (90): $207.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (90): $211.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg (90): $159.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (DilTIAZem HCl ER Coated Beads Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (90): $107.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (90): $130.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (90): $184.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (90): $239.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (90): $921.10</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (DilTIAZem HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (80): $82.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (80): $96.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (80): $103.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Taztia XT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $34.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $41.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (30): $58.82</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $76.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (30): $77.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Tiazac Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $70.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $85.54</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (30): $121.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $157.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (30): $160.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg (30): $168.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, 12-hour</b> (DilTIAZem HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $317.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $362.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $472.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DilTIAZem HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (5 mL): $2.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/10 mL (10 mL): $3.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/25 mL (25 mL): $11.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DilTIAZem HCl-Dextrose Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 5% (100 mL): $21.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125MG/125ML 5% (125 mL): $20.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250MG/250ML 5% (250 mL): $45.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DilTIAZem HCl-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $22.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125MG/125ML 0.9% (125 mL): $22.16</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (DilTIAZem HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $14.51</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Cardizem LA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (30): $136.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $144.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (30): $162.17</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $210.97</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (30): $226.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg (30): $245.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (DilTIAZem HCl ER Coated Beads Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $85.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (30): $96.04</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $124.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (30): $134.41</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg (30): $145.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Matzim LA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">180 mg (30): $89.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 mg (30): $100.05</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $130.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">360 mg (30): $140.03</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 mg (30): $151.67</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Cardizem Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $767.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $1,204.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $2,217.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (DilTIAZem HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $99.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $156.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">90 mg (100): $214.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">120 mg (100): $288.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160641\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acalix (AR, PY, VE);</li>\n      <li>Adizem (IE, LU, SY);</li>\n      <li>Adizem XL (LB, TR);</li>\n      <li>Adizem-CD (IL);</li>\n      <li>Adizem-XL (IE);</li>\n      <li>Aldizem (HR, SI, UA);</li>\n      <li>Altiazem (BG, HK, IT, LV);</li>\n      <li>Altiazem Retard (IT);</li>\n      <li>Altiazem RR (EE, RU);</li>\n      <li>Andico (LK);</li>\n      <li>Angiodrox (ES);</li>\n      <li>Angiotrofen (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Angiotrofin (MX);</li>\n      <li>Angiotrofin Retard (MX);</li>\n      <li>Angiozem (PH);</li>\n      <li>Angizem (IT, LK);</li>\n      <li>Apo-diltiazem CD (NZ);</li>\n      <li>Balcor (BR);</li>\n      <li>Beatizem (SG);</li>\n      <li>Bi-Tildiem (FR);</li>\n      <li>Blocalcin (HU, SK);</li>\n      <li>Calcicard (GB);</li>\n      <li>Calnurs (JP);</li>\n      <li>Cardiazem (KR);</li>\n      <li>Cardil (AE, BD, BG, BH, DK, IS, LT, MY, QA, RU);</li>\n      <li>Cardil Retard (GR);</li>\n      <li>Cardium (SG);</li>\n      <li>Cardizem (AU, BD, BR, DK, FI, NO, NZ, SE);</li>\n      <li>Cardizem CD (AU, BR, NZ);</li>\n      <li>Cardizem Retard (DK, FI, SE, TW);</li>\n      <li>Cardizem SR (BD, BR);</li>\n      <li>Cardizem Unotard (TW);</li>\n      <li>Cordila SR (ID);</li>\n      <li>Cordizem (MY);</li>\n      <li>Corzem (JO);</li>\n      <li>Dasav (MX);</li>\n      <li>Dazil (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MT, OM, SA, SY, YE);</li>\n      <li>Deltazen (FR);</li>\n      <li>Denazox (MT);</li>\n      <li>Diacor LP (FR);</li>\n      <li>Diacordin (SK);</li>\n      <li>Diakordyn (UA);</li>\n      <li>Diladel (IT);</li>\n      <li>Dilatam (ZA);</li>\n      <li>Dilatam 120 SR (IL);</li>\n      <li>Dilatam 240 CD (IL);</li>\n      <li>Dilatame (AT);</li>\n      <li>Dilbres (ID);</li>\n      <li>Dilcardia (BF, BJ, CI, ET, GB, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Dilconton XL-120 (LK);</li>\n      <li>Dilcor (DK);</li>\n      <li>Dilem SR (TH);</li>\n      <li>Dilfar (PT);</li>\n      <li>Dilrene (CZ, FR, HU);</li>\n      <li>Dilta-Hexal (LU);</li>\n      <li>Diltahexal (DE, LU);</li>\n      <li>Diltahexal CD (AU);</li>\n      <li>Diltam (IE);</li>\n      <li>Diltan (BB, BM, BS, BZ, GY, HU, JM, SR, TT);</li>\n      <li>Diltan SR (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Diltelan (KR, TW);</li>\n      <li>Diltelan Depot (IE);</li>\n      <li>Dilteran SR (KR);</li>\n      <li>Diltiazem-B (HU);</li>\n      <li>Diltiazem-Ethypharm (LU);</li>\n      <li>Diltiazem-Xl (LU);</li>\n      <li>Diltiazyn (CO);</li>\n      <li>Diltime (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Dilzanton (DE);</li>\n      <li>Dilzem (AE, AT, AU, BH, CH, CY, CZ, DE, EG, FI, HR, HU, IE, IN, IQ, IR, JO, KW, LB, LK, LY, NZ, OM, PK, PL, QA, RO, SA, SY, TH, YE);</li>\n      <li>Dilzem CD (AU);</li>\n      <li>Dilzem LA (NZ);</li>\n      <li>Dilzem Retard (AE, AT, BH, CY, CZ, DE, EG, IQ, IR, JO, KW, LB, LV, LY, OM, QA, SA, SY, YE);</li>\n      <li>Dilzem RR (CH);</li>\n      <li>Dilzem SR (CY, GB, NZ, VN);</li>\n      <li>Dilzene (IT);</li>\n      <li>Dilzereal 90 Retard (DE);</li>\n      <li>Dilzicardin (DE);</li>\n      <li>Dinisor Retard (ES);</li>\n      <li>DTM (IN);</li>\n      <li>Entrydil (IE);</li>\n      <li>Ergolan (CN);</li>\n      <li>Gadoserin (JP);</li>\n      <li>Hagen (TW);</li>\n      <li>Hart (PY);</li>\n      <li>Helsibon (JP);</li>\n      <li>Herben (KR);</li>\n      <li>Herbesser (JP, MY, TH, TW, VN);</li>\n      <li>Herbesser 180 SR (HK);</li>\n      <li>Herbesser 60 (MY, TH);</li>\n      <li>Herbesser 90 SR (HK, MY, SG, TH);</li>\n      <li>Herbesser R100 (HK, JP);</li>\n      <li>Herbesser R200 (HK, JP);</li>\n      <li>Herbessor (SG);</li>\n      <li>Herbessor 30 (MY);</li>\n      <li>Heresser 90SR (LK);</li>\n      <li>Hesor (TW);</li>\n      <li>Incoril (EC);</li>\n      <li>Iski (IN);</li>\n      <li>Kaizem CD (IN);</li>\n      <li>Lannaher (UA);</li>\n      <li>Lytelsen (JP);</li>\n      <li>Masdil (ES);</li>\n      <li>Metazem (IE);</li>\n      <li>Mono-Tildiem (LU);</li>\n      <li>Mono-Tildiem SR (SG);</li>\n      <li>Monotildiem (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Myonil (DK);</li>\n      <li>Myonil Retard (DK);</li>\n      <li>Neocard (BD);</li>\n      <li>Pazeadin (JP);</li>\n      <li>Progor (LB, TH, TW);</li>\n      <li>Surazem (LU);</li>\n      <li>Tiadil (PT);</li>\n      <li>Tilazem (AR, CL, CO, MX, PE, UY, ZA);</li>\n      <li>Tilazem 90 (ZA);</li>\n      <li>Tildiem (BE, BH, CH, CL, FR, GB, GR, IE, IT, JO, KW, LU, MY, NL, QA, SA, VN);</li>\n      <li>Tildiem CR (NL);</li>\n      <li>Tildiem LA (GB);</li>\n      <li>Tildiem Retard (GR);</li>\n      <li>Tizem (BD);</li>\n      <li>Vasocardol CD (AU);</li>\n      <li>Zaldem (LB);</li>\n      <li>Zandil (PH);</li>\n      <li>Zemtrial (PH);</li>\n      <li>Ziruvate (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Allen LV Jr, Erickson MA 3rd. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(18):2179-2184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8879325/pubmed\" target=\"_blank\" id=\"8879325\">8879325</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists&rsquo; Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apo-Diltiaz (diltiazem) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Badesch DB, Abman SH, Simonneau G, et al, &quot;Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,&quot; <i>Chest</i>, 2007, 131(6):1917-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/17565025/pubmed\" target=\"_blank\" id=\"17565025\">17565025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardizem (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardizem CD (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardizem CD (diltiazem) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cardizem LA (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cartia XT (diltiazem) [prescribing information]. Parsippany, NJ: Actavis; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dilt-XR (diltiazem) [prescribing information]. Weston, FL: Apotex; July 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diltiazem injection [prescribing information]. Lake Forest, IL: Akorn; June 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diltiazem injection [product monograph]. Toronto, Ontario, Canada: Teva Canada Limited; November 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diltiazem injection reconstituted [prescribing information]. Lake Forest, IL: Hospira; January 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ellenbogen KA, Dias VC, and Cardello FP, &quot;Safety and Efficacy of Intravenous Diltiazem in Atrial Fibrillation or Atrial Flutter,&quot; <i>Am J Cardiol</i>, 1995, 75(1):45-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/7801862/pubmed\" target=\"_blank\" id=\"7801862\">7801862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &quot;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn JT and Pasko DA, &quot;Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,&quot; <i>Pediatr Nephrol</i>, 2000, 15(3-4):302-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/11149130/pubmed\" target=\"_blank\" id=\"11149130\">11149130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo; <i>Circulation</i>, 2011, 124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina&mdash;summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). <i>J Am Coll Cardiol</i>. 2003;41(1):159-168.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/12570960/pubmed\" target=\"_blank\" id=\"12570960\">12570960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibson RS, Boden WE, Theroux P, et al, &quot;Diltiazem and Reinfarction With Non-Q-Wave Myocardial Infarction,&quot; <i>N Engl J Med</i>, 1986, 315(7):423-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3526151/pubmed\" target=\"_blank\" id=\"3526151\">3526151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karth GD, Geppert A, Neunteufl T, et al, &quot;Amiodarone vs. Diltiazem for Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias,&quot; <i>Crit Care Med</i>, 2001, 29(6):1149-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/11395591/pubmed\" target=\"_blank\" id=\"11395591\">11395591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &quot;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maron BJ, McKenna WJ, Danielson GK, et al, &quot;American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines,&quot; <i>J Am Coll Cardiol</i>, 2003, 42(9):1687-713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/14607462/pubmed\" target=\"_blank\" id=\"14607462\">14607462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matzim LA (diltiazem) [prescribing information]. Parsippany, NJ: Actavis Pharma; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&quot; <i>Circulation</i>, 2010, 122(18 Suppl 3):729-67.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okada M, Inoue H, Nakamura Y, et al, &quot;Excretion of Diltiazem in Human Milk,&quot; <i>N Engl J Med</i>, 1985, 312(15):992-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3974691/pubmed\" target=\"_blank\" id=\"3974691\">3974691</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips BG, Gandhi AJ, Sanoski CA, et al, &quot;Comparison of Intravenous Diltiazem and Verapamil for the Acute Treatment of Atrial Fibrillation and Atrial Flutter,&quot; <i>Pharmacotherapy</i>, 1997, 17(6):1238-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/9399606/pubmed\" target=\"_blank\" id=\"9399606\">9399606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts SA, Diaz C, Nolan PE, et al, &quot;Effectiveness and Costs of Digoxin Treatment for Atrial Fibrillation and Flutter,&quot; <i>Am J Cardiol</i>, 1993, 72(7):567-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8362772/pubmed\" target=\"_blank\" id=\"8362772\">8362772</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/25840695/pubmed\" target=\"_blank\" id=\"25840695\">25840695</a>]</span><span class=\"doi\">10.1016/j.jash.2015.03.002</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Steele RM, Schuna AA, and Schreiber RT, &quot;Calcium Antagonist-Induced Gingival Hyperplasia,&quot; <i>Ann Intern Med</i>, 1994, 120(8):663-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8135450/pubmed\" target=\"_blank\" id=\"8135450\">8135450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taztia XT (diltiazem) [prescribing information]. Parsippany, NJ: Watson Pharma; September 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;The Effect of Diltiazem on Mortality and Reinfarction After Myocardial Infarction. The Multicenter Diltiazem Postinfarction Trial Research Group,&quot; <i>N Engl J Med</i>, 1988, 319(7):385-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2899840/pubmed\" target=\"_blank\" id=\"2899840\">2899840</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiazac (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant; November 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiazac (diltiazem) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tiazac XC (diltiazem) [product monograph]. Laval, Quebec, Canada: Valeant Canada; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wann SL, Curtis AB, January CT, et al, &quot;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&quot; <i>Circulation</i>, 2011, 123 (1):104-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/21173346/pubmed\" target=\"_blank\" id=\"21173346\">21173346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    White WB, Lacourciere Y, Gana T, et al, &quot;Effects of Graded-Release Diltiazem Versus Ramipril, Dosed at Bedtime, on Early Morning Blood Pressure, Heart Rate, and the Rate-Pressure Product,&quot; <i>Am Heart J</i>, 2004, 148(4):628-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/15459593/pubmed\" target=\"_blank\" id=\"15459593\">15459593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9365 Version 291.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F160657\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F160658\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F160711\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F160662\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F160686\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F160663\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F160664\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F160665\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F160628\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F160613\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F6047983\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F160632\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14471309\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F160631\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475027\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F160720\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F160620\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F160636\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F160617\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F160705\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F160622\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F160653\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F160624\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F160639\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F160640\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F160626\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F160616\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F160635\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F160638\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F160641\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9365|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=diltiazem-patient-drug-information\" class=\"drug drug_patient\">Diltiazem: Patient drug information</a></li><li><a href=\"topic.htm?path=diltiazem-pediatric-drug-information\" class=\"drug drug_pediatric\">Diltiazem: Pediatric drug information</a></li></ul></div></div>","javascript":null}